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Abstract. Malnutrition affects 40-50% of patients with ear, 
nose and throat (ENT) cancer. The aim of this study was to 
assess changes induced by a specific nutritional supplement 
enriched with n-3 polyunsaturated fatty acids, fiber and 
greater amounts of proteins and electrolytes, as compared 
with a standard nutritional supplement, on markers of inflam-
mation, oxidative stress and metabolic status of ENT cancer 
patients undergoing radiotherapy (RT). Fourteen days after 
starting RT, 26 patients were randomly allocated to one of 
two groups, 13 supplemented with Prosure®, an oncologic 
formula enriched with n-3 polyunsaturated fatty acids, fiber 
and greater amounts of proteins and electrolytes (specific 
supplement), and 13 supplemented with Standard-Isosource® 
(standard supplement). Patients were evaluated before RT, and 
14, 28 and 90 days after starting RT. The results showed that 
there were no significant differences between the groups, but 
greater changes were observed in the standard supplement 
group, such as a decline in body mass index (BMI), reduc-
tions in hematocrit, erythrocyte, eosinophil and albumin 
levels, and a rise in creatinine and urea levels. We concluded 
that metabolic, inflammatory and oxidative stress parameters 
were altered during RT, and began to normalize at the end 
of the study. Patients supplemented with Prosure showed an 
earlier normalization of these parameters, with more favor-
able changes in oxidative stress markers and a more balanced 
evolution, although the difference was not significant.
Introduction
Malnutrition affects 40-50% of patients with ear, nose and 
throat (ENT) cancer (1,2). Malnutrition in patients with head 
and neck cancer has been associated with increased rates of 
postoperative complications, a poor response to treatment 
and a greater percentage of tumor recurrence (3). Many of 
these patients require radiation therapy. The radiotherapy 
(RT) alters cellular homeostasis, modifying signal transduc-
tion pathways and the disposition to apoptosis (4). The acute 
toxicity of radiation is mediated by local inflammatory 
phenomena (5) and involves cytokines that are implicated 
in the cachexia-anorexia syndrome (6), such as interleukin 
(IL)-1, IL-6 and tumor necrosis factor (TNF)-α. Radiation 
also generates reactive oxygen species (ROS) by transferring 
energy to certain cellular components, followed by molecular 
changes, with damage to lipids, proteins and DNA. Cells have 
extensive protective mechanisms, such as enzymatic and 
non-enzymatic antioxidants that prevent or limit oxidative 
damage. The cellular superoxide anion generated by ionizing 
radiation can be rapidly dismutated to hydrogen peroxide 
by superoxide dismutase (SOD). Hydrogen peroxide is then 
disposed of by the enzyme glutathione peroxidase (GPx) (7). 
Electrophiles are detoxified by conjugation reactions mediated 
by glutathione S-transferase (GST). ROS can be eliminated or 
inactivated in vivo by various endogenous molecules (e.g., uric 
acid, albumin) or by different exogenous antioxidants derived 
from the diet (8). The sum of endogenous and food-derived 
antioxidants represents the total antioxidant capacity (TAC) of 
the extracellular fluids.
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After irradiation of ENT tissues, the development of 
mucositis, more or less severe, is constant (9). It affects the 
non-keratinized mucosa, soft palate, back of the tongue, floor 
of the mouth and oral cavity. Apart from the mucosal inflam-
mation (10), there is a short fall in production of saliva due to 
the effect of radiation on the salivary glands (11). This results 
in great difficulty when chewing and swallowing food, with 
altered taste and local pain, leading to a decreased intake or 
even inability to eat. The end result is a serious trend in malnu-
trition among patients with ENT tumors undergoing local 
irradiation (12). These patients therefore require a nutritional 
supplement.
Considerable data support the beneficial effect of specific 
supplements and n-3 polyunsaturated fatty acids in the 
prevention and treatment of several chronic diseases, such 
as cardiovascular disease, inflammatory disease and cancer, 
generally related to the ability of n-3 fatty acids to induce 
apoptosis and cell cycle arrest in cancer cells (13,14). The 
intake of n-3 polyunsaturated fatty acids improves the quality 
of life and decreases weight loss in patients with advanced 
pancreatic cancer (15). In addition, n-3 polyunsaturated fatty 
acids can also reduce energy expenditure (16) and exert an 
anti-inflammatory action. However, not all studies agree on 
these positive effects (17).
The aim of the present study was to assess changes induced 
by two different nutritional supplements, one of them enriched 
with n-3 polyunsaturated fatty acids, fiber and greater amounts 
of proteins and electrolytes, on inflammation, oxidative stress 
and metabolic status of ENT cancer patients undergoing RT.
Materials and methods
The study included 26 patients with ENT cancer who required 
treatment with RT. The patients were evaluated following 
the clinical guidelines of the European Society for Clinical 
Nutrition and Metabolism (ESPEN) (18) before starting RT, 
and chemotherapy when it was necessary. Their theoretical 
energy and protein needs were calculated by Harris-Benedict 
equations x activity factor and 1.3-1.5 g of protein per kg of 
weight, respectively. The patients received supplements to fulfill 
their nutritional requirements. Fourteen days after starting RT, 
the 26 ENT cancer patients were allocated by simple random 
sampling (EudraCT 2008-000330-50) into two groups: the 
Prosure® group (n=13) or the Standard-Isosource® group (n=13).
The study was approved by the Ethics Committee of 
Virgen de la Victoria Hospital and was conducted in accor-
dance with the Declaration of Helsinki. All the participants 
gave their signed consent after being fully informed of the 
goal and characteristics of the study.
Study design. This prospective three-month follow-up study 
involved two patterns of a randomly administered nutritional 
intervention given to ENT cancer patients receiving one month 
of RT, to compare a standard nutritional supplement with 
another supplement enriched with n-3 polyunsaturated fatty 
acids, fiber and greater amounts of proteins and electrolytes. 
The experimental group received a supplement of a specific 
enteral formula, Prosure®, which is enriched with n-3 poly-
unsaturated fatty acids and antioxidants (specific supplement) 
(Table I). The control group was also supplemented, but with 
a standard enteral formula, Standard Isosource®, which does 
not contain any extra n-3 polyunsaturated fatty acids (standard 
supplement) (Table I). The specific supplement group received 
a daily supply of 6 g of n-3 polyunsaturated fatty acids 
(3 Prosure® bricks); the rest of their requirements were supplied 
by standard supplements. The adequacy of these supplements 
was evaluated throughout the whole study by anthropometric, 
biochemical and hematologic variables, adjusting the rest 
of the supplements according to the individual needs. Fig. 1 
shows the flow diagram of the progress through the phases of 
the randomized controlled trial. The patients were evaluated 
at baseline before the first dose of RT and 14 days after the 
first dose of RT (time 1), at which point they were randomized 
to either a nutritional supplement enriched with proteins or a 
nutritional supplement enriched with proteins and n-3 polyun-
saturated fatty acids. The patients were then evaluated after 
the 28 days of RT (time 2), and 90 days after initiation of RT 
(time 3). The patients received their nutritional supplements 
from time 1 to time 3.
The study included only patients in TNM stages 3 and 4. 
The exclusion criteria were: age <18 or >80 years, evidence 
of acute or chronic inflammatory disease, infectious disease, 
metastatic disease, prior radiation therapy in the head and neck 
area, edema and/or ascites, malabsorption, and a psychological 
or medical disorder that would prevent the signing of informed 
consent.
The RT technique was as follows: patients were treated 
with 6 MV photons from a linear accelerator equipped with 
a secondary multileaf collimator. All the patients underwent 
computed axial tomography simulation with a thermoplastic 
mask for immobilization, virtual simulation and application of 
a three-dimensional calculation algorithm. The volumes and 
dose specifications were designed according to recommenda-
tions of the International Commission on Radiation Units 
and Measurements (ICRU 50) (19). The patients underwent 
Table I. Nutrient content of the standard and specific supple-
ments.
 Standard supplement Specific supplement
Volume (ml) 250 240
kJ/U 1,102 1236
kJ/ml  4.19  5.03
mOsm/l 292 474
N (g)  1.6  2.6
Proteins (g) 10.2 16
Oligopeptides (%) - 47.5
Carbohydrates (g) 35.5 44
Lipids (g)  8.7  6.1
EPA (g)   1.1
Ratio n6/n3 7/1 0.3/1
Fiber (g) - 2.33
Sodium (mg) 125 360
Potassium (mg) 337 480
kJ, kilojoules; EPA, eicosapentaenoic acid.
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conventional RT (five fractions of 1.8-2 Gy per week) or accel-
erated schedules with concomitant overlay for 4 weeks.
Chemotherapy: the patients received 3 cycles of 100 mg/m2 
of cisplatin (CDDP). Patients deemed unfit for chemotherapy 
(23% of the patients) were offered treatment with cetuximab. 
No significant differences were found between patients with 
and without chemotherapy. The patients received 400 mg/m2 
of cetuximab (shock dose), after which a 250 mg/m2 dose of 
cetuximab was administered concurrently weekly during the 
course of RT.
The patients completed a structured interview to obtain 
the following data: gender, age, medical history and tobacco 
consumption.
Toxicity and response assessments. The National Cancer 
Institute (NCI) Common Toxicity Criteria version 4.0 (20) were 
used for grading toxicities. Patients were monitored for skin, 
hematologic and mucosal toxicity throughout the follow-up 
period. The Karnofsky performance status was also examined.
Laboratory determinations. Fasting venous blood samples 
were drawn at four times: at baseline, 14 days after starting 
RT, immediately after ending RT, and 3 months after ending 
RT. Samples were collected in vacutainers with and without 
ethylenediaminetetraacetic acid and placed on ice. Samples 
were centrifuged at 4,000 rpm for 15 min at 4˚C. Plasma and 
serum were aliquotted and stored at -80˚C until analysis.
Figure 1. Flow diagram of the progress through the phases of the randomized 
controlled trial.
Table II. Characteristics of ENT cancer patients.
 Standard supplement Specific supplement P-value
Gender (male/female) 10/3 11/2 0.619
Age (years) 61.08±10.68 61.00±14.66 0.724
BMI (kg/m2) 27.53±3.97 25.27±4.63 0.311
Smoking status
  Non-smokers 4 (30.8) 3 (23.1) 0.705
  Ex-smokers 7 (53.8) 7 (53.8) 1.000
  Smokers 2 (15.4) 3 (23.1) 0.655
Tumor localization
  Cavum 1 (7.7) 3 (23.1) 0.317
  Oral cavity 2 (15.4) 1 (7.7) 0.564
  Oropharynx 2 (15.4) 2 (15.4) 1.000
  Larynx 7 (53.8) 6 (46.2) 0.782
  Others 1 (7.7) 1 (7.7) 1.000
Cancer stage
  III 6 (46.2) 4 (30.8) 0.527
  IV 7 (53.8) 9 (69.2) 0.617
Karnofsky performance status
    70 1 (7.7) 2 (15.4) 0.564
    80 4 (30.8) 2 (15.4) 0.414
    90 4 (30.8) 4 (30.8) 1.000
  100 4 (30.8) 5 (38.5) 0.739
Values are presented as mean ± SD or n (%). Differences in frequency distribution between groups were assessed by the Fisher test.
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Serum biochemical parameters were measured in duplicate. 
Serum glucose (Randox Laboratories Ltd., Antrim, UK), uric 
acid (Dimension autoanalyzer; Dade Behring Inc. Deerfield, 
IL, USA), albumin, creatinine and urea (Siemens Healthcare 
Diagnostics Inc., Newark, DE, USA) were measured using 
standard enzymatic methods. C reactive protein (CRP) and 
IL-6 levels were measured using a human CRP Quantikine 
ELISA kit from R&D Systems (Abingdon, UK) and a human 
IL-6 Quantikine ELISA from R&D Systems according to the 
manufacturer's instructions. TAC, GPx, GST, and SOD activi-
ties were measured in plasma with commercial kits (Cayman 
Chemical, Ann Arbor, MI, USA). The intra- and inter-assay 
coefficients of variation (CV) of TAC were 3.4 and 3.0%, 
respectively. The intra- and inter-assay CV of GPx were 5.7 
and 7.2%, respectively. The intra- and inter-assay CV of GST 
were 4.1 and 7.9%, respectively. The intra- and inter-assay 
CV of SOD were 3.2 and 3.7%, respectively. LPO levels 
were measured in serum using a commercial kit (Cayman 
Chemical).
Statistical analysis. The sample size was calculated for the 
main variable, oxidative stress: TAC [standard deviation 
(SD) =0.112 and mean difference =0.17] (21), with 95% power 
and an α error of 0.05. Sample size of each group: n=13.
The results are given as the mean ± SD. All clinical param-
eters are summarized by descriptive statistics. Information at 
each visit was compared by the Student's t-test for parametric 
variables and by the Friedman test for non-parametric vari-
ables. Differences in frequency distribution of qualitative 
variables between groups were assessed by the Fisher test. 
The Wilcoxon test for paired samples was used to compare 
oxidative stress, and biochemical and hematologic parameters 
between time 0 and the other times, and between time 1 
and the others times (Bonferroni correction was applied). 
The Mann-Whitney U test was used to compare the studied 
variables between the two supplement groups. The Spearman 
correlation coefficient was calculated to estimate the linear 
correlations between variables. In all cases, the rejection level 
for a null hypothesis was α=0.05 for two tails. The statistical 
analysis was carried out with SPSS (version 15.0 for Windows; 
SPSS Inc., Chicago, IL, USA).
Results
Table II shows the characteristics of the ENT cancer patients, 
with no significant differences between the groups.
The consumption of n-3 polyunsaturated fatty acids in each 
group at different times is shown in Table III, with similar 
Table III. Distribution of hematological variables during the prospective study in patients with the standard supplement and the 
specific supplement.
 0 1 P-value 2 P-value 3 P-value P-value
Standard supplement:
n-3 acids from diet (g/d) 0.3±0.2 0.3±0.1  0.3±0.2  0.2±0.3  0.767
Basophils (x103/µl) 0.04±0.02 0.05±0.05  0.05±0.03  0.06±0.05c  0.958
Hematocrit (%) 40±6.6 38.1±6.9  36.3±6.2 0.019a 36.4±6.3 0.019a 0.050
Erythrocytes (x106/µl) 4.4±0.7 3.9±0.6 0.007a 3.8±0.6 0.003a 4.1±0.7  0.009
Hemoglobin (gr/dl) 13.4±2.1 12.4±1.9 0.021a 12.1±2 0.021a 12.1±2.4 0.010a 0.054
Leukocytes (x103/µl) 7.2±2.6 5.5±2.4  6.2±2.6  6.2±2.6  0.177
Lymphocytes (x103/µl) 1.5±0.6 0.7±0.3 0.001a 0.7±0.3 0.030a 0.9±0.4c 0.003a <0.001
       0.039b
Eosinophils (x103/µl) 0.2±0.1 0.1±0.1  0.1±0.04 0.049a 0.1±0.1  0.063
     0.014b
Specific supplement:
n-3 acids from diet 
and supplement (g/d) 0.299±0.363 0.295±0.164  1.006±0.264 0.003a 0.936±0.357 0.004a 0.043
     0.002b  0.003b
Basophils (x103/µl) 0.1±0.04 0.04±0.02 0.002a 0.1±0.03  0.03±0.03c 0.002a <0.001
Hematocrit (%) 38.7±5.2 35.9±3.5  35.3±3.5  34.9±5.2 0.033a 0.049
Erythrocytes (x106/µl) 4.2±0.6 3.9±0.5 0.041a 3.8±0.4 0.041a 3.8±0.5 0.034a 0.082
Hemoglobin (gr/dl) 12.9±1.8 11.9±1.2  11.5±1 0.028a 11.6±1.6 0.015a 0.015
Leukocytes (x103/µl) 8.6±3 6.9±3.7  6.1±2.7 0.015a 6.2±3.4  0.075
Lymphocytes (x103/µl) 1.6±0.6 0.9±0.8 0.034a 0.6±0.2 0.002a 0.8±0.4c 0.004a <0.001
Eosinophils (x103/µl) 0.2±0.2 0.2±0.1  0.2±0.1  0.1±0.1  0.193
Values are presented as mean ± SD. P-value, statistical differences among different times in the same group of supplement according to the 
Friedman test. aStatistically significant differences between time 0 and the other times in the same group of supplement. bStatistically significant 
differences between time 1 and the other times in the same group of supplement. cStatistically significant differences between time 0 and the 
other times between the standard and the specific supplement group (P<0.05).
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levels at times 0 and 1. Significant differences between the 
groups were observed after the patients were randomized to 
a standard or specific nutritional supplement, at times 2 and 3 
(P=0.027 and 0.023, respectively).
Furthermore, Table III also summarizes the differences in 
hematological variables. Both groups experienced a parallel 
evolution; however, variables showed more significant 
differences in the standard supplement patients throughout 
the study. We observed that the standard supplement patients 
experienced significant changes in hematocrit, erythro-
cytes and eosinophils during the study. On the other hand, 
significant changes in basophils, hematocrit, hemoglobin 
and lymphocytes were found in the specific supplement 
group. When comparing the two groups, the basophil and 
lymphocyte levels were significantly lower between times 0 
and 3 in the specific supplement group (P=0.002 and 0.035, 
respectively).
The Karnofsky and toxicity values remained similar in 
both groups of patients throughout the study. During RT, the 
Karnofsky values decreased and toxicity markers increased. 
Two months after the end of RT, the Karnofsky and toxicity 
markers improved (Table IV).
In both treatment groups, the body mass index (BMI) 
decreased significantly at first and recovered later with no 
significant differences, although a smaller decline in BMI was 
observed in the specific supplement patients (Table V).
Table IV. Distribution of the Karnofsky and toxicity values during the prospective study in both groups of patients.
A, Karnofsky
 Standard supplement (n=13) Specific supplement (n=13)
 ------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------
 60 70 80 90 100 60 70 80 90 100 P-value
Time 0 0 1 4 4 4 0 2 2 4 5 0.774
Time 1 0 4 1 6 2 0 3 3 4 3 0.627
Time 2 1 4 1 5 2 2 2 4 3 2 0.509
Time 3 0 2 3 5 3 1 1 3 4 4 0.811
B, Hematologic toxicity
 Standard supplement (n=13) Specific supplement (n=13)
 ----------------------------------------------------------------- -----------------------------------------------------------------
 0 1 2 0 1 2 P-value
Time 1   7 4 2 10 2 1 0.465
Time 2 11 1 1 10 2 1 0.827
Time 3 13 0 0 13 0 0 -
C, Mucosal toxicity
 Standard supplement (n=13) Specific supplement (n=13)
 --------------------------------------------------------------------------------- --------------------------------------------------------------------------------
 0 1 2 3 4 0 1 2 3 4 P-value
Time 1 0 2 9 2 0 0 4 5 4 0 0.290
Time 2 0 0 5 8 0 2 0 4 7 0 0.337
Time 3 5 7 1 0 0 4 5 2 1 1 0.596
D, Skin toxicity
 Standard supplement (n=13) Specific supplement (n=13)
 --------------------------------------------------------------------------- ---------------------------------------------------------------------------
 0 1 2 3 0 1 2 3 P-value
Time 1   1 3 7 2   1 4 6 2 0.974
Time 2   2 2 5 4   4 4 2 3 0.430
Time 3 11 2 0 0 10 2 0 1 0.592
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Concerning the biochemical variables (Table V), both 
groups experienced significant changes in levels of urea and, 
unexpectedly, in levels of albumin in the specific supplement 
group. Comparing both groups, we found that uric acid levels 
behaved differently according to the group. Patients receiving 
the standard supplement had significantly higher levels of uric 
acid whereas the patients receiving the enriched supplement 
had significantly lower levels of uric acid at time 3. Creatinine 
levels were also significantly increased at time 2 in the patients 
who received the standard supplement.
Regarding inflammatory variables, levels of CRP and 
IL-6 changed significantly in the specific supplement group 
(P=0.028 and 0.025, respectively) during the study. CRP 
levels were higher during RT at times 1 and 2 in both groups 
compared with time 0 (Fig. 2A) whereas levels of IL-6 rose 
at time 1 in both groups, more so in the specific supple-
Table V. Distribution of BMI and biochemical variables during the prospective study in patients with the standard supplement 
and the specific supplement.
 0 1 P-value 2 P-value 3 P-value P-value
Standard supplement: n-3 acids from diet
BMI (kg/m2) 27.5±3.9 26.5±4.1 0.010a 25.79±4.40 0.003a 26.09±4.72  0.004
     0.010b
Glucose (mmol/l) 7.9±4 8.4±4.7  8.31±5.29  5.85±1.84 0.017b 0.095
Albumin (g/dl) 3.6±0.4 3.3±0.4  3.230±0.673  3.400±0.710  0.177
Uric acid (mmol/l) 0.3±0.1 0.3±0.1  0.3±0.2  0.3±0.1c 0.005a 0.081
       0.016b
Creatinine (µmol/l) 77.1±17.5 88.4±25.5  110.8±62.2d 0.008a 85.3±16.8  0.088
Urea (mmol/l) 5.7±2.5 8.5±5.1 0.008a 12.5±10.4 0.005a 6.9±3.5 0.044a 0.001
       0.028b
Specific supplement: n-3 acids from diet and supplement
BMI (kg/m2) 25.3±4.6 24.7±4.5  24.±4.4 0.011a 24.4±4.4  0.035
     0.023b
Glucose (mmol/l) 5.9±2. 6.7±1.9  6.5±3.5  5.6±2.4  0.198
Albumin (g/dl) 3.8±0.3 3.6±0.4 0.048a 3.4±0.2 0.012a 3.8±0.5 0.025b 0.013
Uric acid (mmol/l) 0.3±0.1 0.3±0.1  0.2±0.1  0.2±0.1c  0.281
Creatinine (µmol/l) 66.7±19.5 78.9±25.6 0.036a 72.4±18d  74.1±17.8  0.261
Urea (mmol/l) 5.8±2.1 7.9±4.2 0.027a 7.7±3.3 0.023a 8.5±4.9  0.020
Values are presented as mean ± SD. P-value, statistical differences among different times in the same group of supplement according to the 
Friedman test. aStatistically significant differences between time 0 and the other times in the same group of supplement. bStatistically significant 
differences between time 1 and the other times in the same group of supplement. cStatistically significant differences between time 0 and the 
other times between the standard and the specific supplement group (P<0.05). dStatistically significant differences between time 1 and the other 
times between the standard and the specific supplement group (P<0.05).
Figure 2. Distribution of inflammatory parameters (A and B), during the prospective study, in patients with the standard supplement (grey) and the specific 
supplement (black). The Wilcoxon test for paired samples was used to compare oxidative stress parameters between time 0 and the other times, and between 
time 1 and the others times (Bonferroni correction was applied). aStatistically significant differences between time 0 and the other times. bStatistically 
significant differences between time 1 and the other times (P≤0.05).
  A   B
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ment group, but then fell in both groups at the other times 
(Fig. 2B).
The oxidants and antioxidant variables, LPO, GPx, SOD 
and TAC activity, changed significantly during the study in the 
specific group but not in the standard group (P=0.036, 0.029, 
0.045 and 0.036, respectively). No significant differences 
were found for GST. In both groups, TAC and SOD activity 
increased significantly at the end of the study (time 3), and 
levels of LPO decreased significantly at the end of RT and at 
the end of the study (times 2 and 3) in patients who received 
the specific supplement (Fig. 3).
Significant negative correlations were observed between 
the Karnofsky values and inflammation parameters. The 
Karnofsky correlated with IL-6 levels at time 0 (Rs=-0.420, 
P<0.05, respectively), with CRP and IL-6 levels at time 1 
(Rs=-0.470, P<0.05 and Rs=-0.394, P<0.05, respectively), and 
with CRP and IL-6 levels at time 3 (Rs=-0.684, P<0.001 and 
Rs=-0.631, P<0.005, respectively). Hematologic toxicity corre-
lated negatively with TAC (Rs=-0.536, P<0.005).
Discussion
Cancer patients suffer metabolic and analytical abnormalities 
due to the disease and its treatments. RT often results in hema-
tological and immune dysplasia as hematological stem cells are 
damaged during the procedures and committed hematologic 
and immune cells are then depleted (21,22). During the study, 
the hematologic variables decreased in both groups. These 
changes were more significant in the standard supplement 
patients. It thus seems that the hematologic variables of the 
patients taking the standard supplement were more affected 
by the treatment.
Cancer-associated weight loss is due in part to the lower 
food intake, particularly in ENT cancer patients for whom 
food intake frequently presents a real challenge. In addi-
tion, RT results in such conditions as mucositis, dysphagia 
or xerostomia, which promote weight loss; in addition, these 
symptoms all worsen if chemoradiation therapy (chemoRT) 
is needed. In our study, BMI and Karnofsky values decreased 
Figure 3. Distribution of oxidative stress parameters (A-E), during the prospective study, in patients with the standard supplement (grey) and the specific 
supplement (black). The Wilcoxon test for paired samples was used to compare oxidative stress parameters between time 0 and the other times, and between 
time 1 and the other times (Bonferroni correction was applied). aStatistically significant differences between time 0 and the other times. bStatistically signifi-
cant differences between time 1 and the other times (P≤0.05).
  A   B
  C   D
  E
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and toxicity markers increased during RT. Two months later, 
these three variables improved. Some studies have evaluated 
weight loss in head and neck cancer patients and found that 
reductions in intake and weight were significantly greater in 
chemoRT than in RT patients (23).
We observed that albumin levels decreased at time 2, 
significantly so in the specific supplement group, and tended 
to normalize, almost reaching baseline levels at time 3. This 
is in agreement with previous studies which reported that RT 
decreased albumin levels (24) and n-3 polyunsaturated fatty 
acids increased serum albumin (25). However, we observed 
no significant benefit with the specific supplement regarding 
albumin levels.
Uric acid production is greatly increased after treatment 
with chemotherapy or RT as a result of increased purine break-
down. After RT, the two groups of patients showed a different 
behavior. The standard supplement patients showed a signifi-
cant increase in levels of uric acid at the end of the study, whilst 
the specific supplement patients showed a significant decrease. 
Several studies have reported that n-3 polyunsaturated fatty 
acids reduce levels of uric acid (26,27). One explanation for 
this is that n-3 polyunsaturated fatty acids seem to reduce the 
end products of xanthine oxidase activity. The levels of urea 
increased significantly in both groups, more so than in the 
specific supplement patients, during and after the RT. The rate 
of urea production is an indicator of net protein catabolism, 
which increases significantly during periods of severe meta-
bolic stress (28). In addition, urea production (28) and levels of 
uric acid (29) increase with the advancing tumor state. Thus, 
the patients receiving the specific supplement seem to have 
experienced less metabolic stress.
The inflammatory parameters CRP and IL-6 correlated 
negatively with the Karnofsky performance status. During the 
RT, inflammatory parameters were increased in both groups 
of patients. Exposure to radiation initiates a programmed 
molecular and cellular response to promote tissue repair, which 
includes the upregulation of proinflammatory cytokines (30). 
It is well-known that inflammation is a critical component of 
tumor progression and that nutritional supplements seem to 
improve inflammatory parameters, with contradictory findings 
in the literature between the specific and standard supple-
ments (31). After 14 days of nutritional supplements (time 2), 
IL-6 levels began to decrease, and, at the end of the study, the 
IL-6 levels were significantly decreased and the CRP levels 
were normalized. Both CRP (29,32-34) and IL-6 (35-38) have 
a prognostic value in head and neck tumors, through direct 
relations with tumor state, tumor progression, metastasis and 
tumor response to treatment, and therefore in disease-free 
survival and overall survival. Some studies observed that 
blocking IL-6 signaling attenuated aggressive tumor behavior 
and sensitized the cells to treatments (39). Thus, any interven-
tion which decreases levels of IL-6 (40) and/or CRP would 
have beneficial effects on tumor prognosis. In addition, CRP 
may be an objective and sensitive marker of radiation-induced 
mucositis (41) and an independent predictor of weight loss (23).
On the one hand, ENT cancer has a strong link to oxida-
tive damage and stress, such as tobacco and alcohol, both 
sources of massive quantities of ROS, and, on the other hand, 
ionizing radiation causes severe cellular damage and stress, 
both directly by energetic disruption of DNA integrity and 
indirectly as a result of the formation of intracellular free radi-
cals (42). Thus, parameters of oxidative stress could represent 
a useful tool for predicting the prognosis of head and neck 
cancer (43). In the present study we, as others (31,44), observed 
that subjects receiving RT, whichever nutritional supplement 
they were taking, displayed parameters of oxidative stress that 
were altered by the RT and that the TAC correlated negatively 
with toxicity. At the end of the study, oxidative stress param-
eters showed a trend towards normalization, although these 
alterations in the patients who received the specific supple-
ment normalized to baseline levels earlier than in the group 
receiving the standard supplement. The antioxidant param-
eters and LPO levels also improved significantly two months 
after ending the RT. There have been conflicting reports on the 
effects of n-3 polyunsaturated fatty acid supplementation on 
oxidant/antioxidant status in humans (45,46). Several studies 
have observed significant associations in head and neck cancer 
between SOD and GPx activity and better disease-specific 
survival and postoperative RT (47), between manganese 
SOD and tumor migration and invasion (48), and between 
the loss of GPx expression and tumor chemoresistance (49), 
all important prognostic factors for survival. There is also 
a deranged antioxidant defense system due to significantly 
low levels of TAC (50) and higher levels of nitric oxide and 
GST in these cancer patients, with a significant increase after 
RT (51). By contrast, we found no significant differences in 
GST. Our results suggest that the supplement enriched with 
n-3 polyunsaturated fatty acids prevents patients from expe-
riencing abrupt changes in oxidative stress parameters during 
treatment. It has been postulated that n-3 polyunsaturated fatty 
acids may reduce oxidative stress by allowing a reduction in the 
disease inflammatory activity, thus decreasing the production 
of free radicals, or by acting as a free radical scavenger (52). 
Moreover, docosahexaenoic acid has a protective effect against 
H2O2-induced oxidative stress in human lymphocytes (53).
We recognize several limitations in this study, such as 
the small patient population sample, the heterogeneous and 
contradictory publications evaluating the immunonutrition 
support with which to compare our results, and the dietary 
intervention itself, which was more than just n-3 polyunsatu-
rated fatty acids. The contradictory data could be explained 
by the differences in nutritional support formulas. We tried 
to reduce this limitation by providing only 3 Prosure bricks 
per day in the specific supplement group whereas the rest of 
their requirements were supplied by standard supplements. In 
addition, pathophysiological changes in cancer patients make 
it difficult to establish causal relationships. Nevertheless, it 
appears that a formula containing amino acids, n-3 fatty acids 
and ribonucleic acids could modulate the inflammatory and 
antioxidant response.
In conclusion, cancer and its treatment, including chemo-
therapy and RT, produce metabolic stress and alterations in 
parameters of inflammation and oxidative stress. Nutritional 
supplements seem to improve these alterations, leading to a 
better health status in these ENT cancer patients. The nutri-
tional intervention appears to influence the oxidative and 
inflammation state. The specific supplement does not produce 
significantly long-lasting differences in markers of inflamma-
tion, but it does produce more favorable changes in markers 
of oxidative stress, less metabolic stress and, in general, a 
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more balanced evolution with respect to the standard diet. 
These changes do not produce changes in quality of life over 
the short term. Finally, a long-term follow-up could provide 
additional insights into the effect of nutritional supplements 
on quality of life.
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